

2017 Webinar #4: Maternal Opiate Use and Neonatal Abstinence Syndrome August 22, 2017

References

ACOG Committee ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119:1070–1076.

Arjune D, Bodnar RJ. Post-natal morphine differentially affects opiate and stress analgesia in adult rats. Psychopharmacology (Berl) 1989;98:512–517.

Aroyewun O, Barr GA. The effects of opiate antagonists on milk intake of preweanling rats. Neuropharmacology. 1982;21:757–762.

Aroyewun OO, Barr GA. Effects of chronic antenatal and postnatal administration of narcotics on naloxone-induced anorexia in preweanling rats. Neuropharmacology. 1983;22:329–336.

Bakstad B, Sarfi M, Welle-Strand GK, Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. A national prospective study. Eur Addict Res. 2009;15:128–134.

Bardo MT, Bhatnagar RK, Gebhart GF. Differential effects of chronic morphine and naloxone on opiate receptors, monoamines, and morphine-induced behaviors in preweanling rats. Brain Res. 1982;256:139–147.

Bardo MT, Bhatnagar RK, Gebhart GF. Age-related differences in the effect of chronic administration of naloxone on opiate binding in rat brain. Neuropharmacology. 1983;22:453–461.

Barg J, Simantov R. Developmental profile of kappa, mu and delta opioid receptors in the rat and guinea pig cerebellum. Dev Neurosci. 1989;11:428–434.

Bashore RA, Ketchum JS, Staisch KJ, Barrett CT, Zimmermann EG. Heroin addiction and pregnancy. West J Med. 1981;134:506–514.

Beckwith AM, Burke SA. Identification of early developmental deficits in infants with prenatal heroin, methadone, and other opioid exposure. <u>Clin Pediatr (Phila)</u>. 2015 Apr;54(4):328-35.

Belcheva MM, Bohn LM, Ho MT, Johnson FE, Yanai J, Barron S, et al. Brain opioid receptor adaptation and expression after prenatal exposure to buprenorphine. Brain Res Dev Brain Res. 1998;111:35–42.



Belcheva MM, Dawn S, Barg J, McHale RJ, Ho MT, Ignatova E, et al. Transient down-regulation of neonatal rat brain mu-opioid receptors upon in utero exposure to buprenorphine. Brain Res Dev Brain Res. 1994;80:158–162.

Binder T, Vavrinkova B. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett. 2008;29:80–86.

Brown HL, Britton KA, Mahaffey D, Brizendine E, Hiett AK, Turnquest MA. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol. 1998;179:459–463.

Bunikowski R, Grimmer I, Heiser A, Metze B, Schafer A, Obladen M. Neurodevelopmental outcome after prenatal exposure to opiates. Eur J Pediatr. 1998;157:724–730. [PubMed]

Chasnoff IJ, Hatcher R and Burns WJ. Early Growth Patterns of Methadone-Addicted Infants. Am J Dis Child 134:1049-1051, 1980.

Chasnoff IJ, Diggs G, Schnoll S. Fetal Alcohol Effects and Maternal Cough Syrup Abuse. A case report. Am J Dis Child 135:968, 1981.

Chasnoff IJ, Burns WJ and Hatcher R. Polydrug - and Methadone -Addicted Newborns: a Continuum of Impairment? Pediatrics 70:210 -212, 1982.

Chasnoff IJ, Burns WJ and Schnoll SH. Perinatal Addiction: Maternal Narcotic vs. Non-narcotic Use During Pregnancy and its Effects on Infant Development. In: <u>Problems of Drug Dependence 1983.</u> 49:220-226, N.I.D.A., 1984.

Chasnoff IJ and Burns WJ. The Moro Reaction: A Scoring System for Neonatal Narcotic Withdrawal. Develop Med Child Neurol 26:484-489, 1984.

Chasnoff IJ. Effects of Maternal Narcotic vs. Non-narcotic Addiction on Neonatal Neurobehavior and Infant Development. In: <u>Current Research on the Consequences of Maternal Drug Use</u>, T.M. Pinkert (ed.), N.I.D.A. Washington, D.C. 59:84-95, 1985.

Chasnoff IJ, Gardner S. Neonatal abstinence syndrome: A policy perspective. Journal of Perinatology. 2015;35:539-541.

Chiang YC, Hung TW, Lee CW, Yan JY, Ho IK. Enhancement of tolerance development to morphine in rats prenatally exposed to morphine, methadone, and buprenorphine. J Biomed Sci. 2010;17:46. [PMC free article] [PubMed]



Cleary BJ, Eogan M, O'Connell MP, Fahey T, Gallagher PJ, Clarke T, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction. 2012;107:1482–1492.[PubMed]

Coyle MG, Salisbury AL, Lester BM, Jones HE, Lin H, Graf-Rohrmeister K, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction. 2012;107:63–73.

de Cubas MM, Field T. Children of methadone-dependent women: developmental outcomes. Am J Orthopsychiatry. 1993;63:266–276.

De Montis GM, Devoto P, Angioi RM, Curreli V, Tagliamonte A. *In utero* exposure to methadone produces a stable decrease of the cortex 5-HT transport system in rats. Eur J Pharmacol. 1983;90:57–63.

De Vries TJ, Van Vliet BJ, Hogenboom F, Wardeh G, Van der Laan JW, Mulder AH, et al. Effect of chronic prenatal morphine treatment of mu-opioid receptor-regulated adenylate cyclase activity and neurotransmitter release in rat brain slices. Eur J Pharmacol. 1991;208:97–104.

Enters EK, Guo HZ, Pandey U, Ko DJ, Robinson SE. The effect of prenatal methadone exposure on development and nociception during the early postnatal period of the rat. Neurotoxicol Teratol. 1991;13:161–166.

Eriksson PS, Ronnback L. Effects of prenatal morphine treatment of rats on mortality, bodyweight and analgesic response in the offspring. Drug Alcohol Depend. 1989;24:187–194.

Fajemirokun-Odudeyi O, Sinha C, Tutty S, Pairaudeau P, Armstrong D, Phillips T, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol. 2006;126:170–175.

Farid WO, Dunlop SA, Tait RJ, Hulse GK. The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. Curr Neuropharmacol. 2008;6:125–150.

Farid WO, Lawrence AJ, Krstew EV, Tait RJ, Hulse GK, Dunlop SA. Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood. PLoS One. 2012;7:e52812.

Finnegan LP, Connaughton JF, Jr, Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. Addict Dis. 1975;2:141–158.

Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M, et al. Treatment of opioid-dependent pregnant women with buprenorphine. Addiction. 2000;95:239–244.



Ford DH, Rhines RK. Prenatal exposure to methadone HCL in relationship to body and brain growth in the rat. Acta Neurol Scand. 1979;59:248–262.

Gill AC, Oei J, Lewis NL, Younan N, Kennedy I, Lui K. Strabismus in infants of opiate-dependent mothers. Acta Paediatr. 2003;92:379–385.

Guo HZ, Enters EK, McDowell KP, Robinson SE. The effect of prenatal exposure to methadone on neurotransmitters in neonatal rats. Brain Res Dev Brain Res. 1990;57:296–298.

Guo X, Spencer JW, Suess PE, Hickey JE, Better WE, Herning RI. Cognitive brain potential alterations in boys exposed to opiates: in utero and lifestyle comparisons. Addict Behav. 1994;19:429–441.

Hammer RP, Jr, Seatriz JV, Ricalde AR. Regional dependence of morphine-induced mu-opiate receptor down-regulation in perinatal rat brain. Eur J Pharmacol. 1991;209:253–256.

Hans SL. 1989Developmental consequences of prenatal exposure to methadone Ann N Y Acad Sci 562195–207.

Harlan RE, Song DD. Prenatal morphine treatment and the development of the striatum. Regul Pept. 1994;54:117–118.

Hauser KF, McLaughlin PJ, Zagon IS. Endogenous opioids regulate dendritic growth and spine formation in developing rat brain. Brain Res. 1987;416:157–161.

Hauser KF, McLaughlin PJ, Zagon IS. Endogenous opioid systems and the regulation of dendritic growth and spine formation. J Comp Neurol. 1989;281:13–22.

Hou Y, Tan Y, Belcheva MM, Clark AL, Zahm DS, Coscia CJ. Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling. Brain Res Dev Brain Res. 2004;151:149–157.

Hulse GK, Milne E, English DR, Holman CD. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction. 1997;92:1571–1579..

Hulse GK, Milne E, English DR, Holman CD. Assessing the relationship between maternal opiate use and neonatal mortality. Addiction. 1998;93:1033–1042.

Hunt RW, Tzioumi D, Collins E, Jeffery HE. Adverse neurodevelopmental outcome of infants exposed to opiate in-utero. Early Hum Dev. 2008;84:29–35. [PubMed]

Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag. 2009;5:47–55.



Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998;25:139–151.

Kandall SR, Albin S, Lowinson J, Berle B, Eidelman AI, Gartner LM. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics. 1976;58:681–685.

Maas U, Kattner E, Weingart-Jesse B, Schafer A, Obladen M. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. J Perinat Med. 1990;18:111–118.

Martinez A, Kastner B, Taeusch HW. Hyperphagia in neonates withdrawing from methadone. Arch Dis Child Fetal Neonatal Ed. 1999;80:F178–F182.

McLaughlin PJ, Tobias SW, Lang CM, Zagon IS. Opioid receptor blockade during prenatal life modifies postnatal behavioral development. Pharmacol Biochem Behav. 1997;58:1075–1082.

McLaughlin PJ, Zagon IS, White WJ. Perinatal methadone exposure in rats. Effects on body and organ development. Biol Neonate. 1978;34:48–54.

Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. 2013Maintenance agonist treatments for opiate-dependent pregnant women Cochrane Database Syst Rev12CD006318.

Ornoy A, Michailevskaya V, Lukashov I, Bar-Hamburger R, Harel S. The developmental outcome of children born to heroin-dependent mothers, raised at home or adopted. Child Abuse Negl. 1996;20:385–396.

Ornoy A, Segal J, Bar-Hamburger R, Greenbaum C. 2001Developmental outcome of school-age children born to mothers with heroin dependency: importance of environmental factors Dev Med Child Neurol 43668–675.

Parikh R, Hussain T, Holder G, Bhoyar A, Ewer AK. Maternal methadone therapy increases QTc interval in newborn infants. Arch Dis Child Fetal Neonatal Ed. 2011;96:F141–F143.

Paul JA, Logan BA, Krishnan R, Heller NA, Morrison DG, Pritham UA, et al. Development of auditory event-related potentials in infants prenatally exposed to methadone. Dev Psychobiol. 2014;56:1119–1128.

Ricalde AA, Hammer RP., Jr Perinatal opiate treatment delays growth of cortical dendrites. Neurosci Lett. 1990;115:137–143.

Robinson SE, Wallace MJ. Effect of perinatal buprenorphine exposure on development in the rat. J Pharmacol Exp Ther. 2001;298:797–804.



Rosen TS, Johnson HL. Long-term effects of prenatal methadone maintenance. NIDA Res Monogr. 1985;59:73–83.

Sanchez ES, Bigbee JW, Fobbs W, Robinson SE, Sato-Bigbee C. 2008Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain Glia 561017–1027.

Sarfi M, Martinsen H, Bakstad B, Roislien J, Waal H. Patterns in sleep-wakefulness in three-month old infants exposed to methadone or buprenorphine. Early Hum Dev. 2009;85:773–778.

Schindler SD, Eder H, Ortner R, Rohrmeister K, Langer M, Fischer G. Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy. Addiction. 2003;98:103–110.

Soepatmi S. Developmental outcomes of children of mothers dependent on heroin or heroin/methadone during pregnancy. Acta Paediatr Suppl. 1994;404:36–39.

Sundelin Wahlsten V, Sarman I. Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediatr. 2013;102:544–549.

Vargas GC, Pildes RS, Vidyasagar D, Keith LG. Effect of maternal heroin addiction on 67 liveborn neonates. Clin Pediatr (Phila) 1975;14:751–753.

Welle-Strand GK, Skurtveit S, Jones HE, Waal H, Bakstad B, Bjarko L, et al. Neonatal outcomes following *in utero* exposure to methadone or buprenorphine: A National Cohort Study of opioidagonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug Alcohol Depend. 2013;127:200–206. [PubMed]

Wilson GS, Desmond MM, Wait RB. Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications. J Pediatr. 1981;98:716–722.

Zagon IS, McLaughlin PJ. Effect of chronic maternal methadone exposure on perinatal development. Biol Neonate. 1977;31:271–282.

Zagon IS, McLaughlin PJ. 1987Endogenous opioid systems regulate cell proliferation in the developing rat brain Brain Res 41268–72.

Zagon IS, McLaughlin PJ, Thompson CI. Learning ability in adult female rats perinatally exposed to methadone. Pharmacol Biochem Behav. 1979;10:889–894.